
Supplementary Material

Potent and Selective Inhibitors of Human Monoamine Oxidase A from an Endogenous Lichen Fungus *Diaporthe mahothocarpus*

Geum Seok Jeong ¹, Prima F. Hillman ², Myung-Gyun Kang ³, Sungbo Hwang ³, Jong-Eun Park ¹, Sang-Jip Nam ², Daeui Park ³ and Hoon Kim ^{1,*}

¹ Department of Pharmacy, and Research Institute of Life Pharmaceutical Sciences, Sunchon National University, Suncheon 57922, Republic of Korea; fever41@naver.com (G.S.J.); nji8009@naver.com (J.I.N.); park140201@naver.com (J.E.P.); sungtae@scnu.ac.kr (S.T.Y.)

² Department of Chemistry and Nanoscience, Ewha Womans University, Seoul 03760, Republic of Korea; primafitriah@gmail.com (P.F.H.); sjnam@ewha.ac.kr (S.J.N.)

³ Department of Predictive Toxicology, Korea Institute of Toxicology, Daejeon 34114, Republic of Korea; myung-gyun.kang@kitox.re.kr (M.-G.K.); sungbo.hwang@kitox.re.kr(S.H.); daeui.park@kitox.re.kr (D.P.)

* Correspondence: Correspondence: hoon@sunchon.ac.kr; Tel.: +82-61-750-3751

Table of Contents

Figure S1. Percentage purity of AT (1)

Figure S2. Percentage purity of HAT (2)

Figure S3. Percentage purity of MED (3)

Figure S4. ¹H NMR spectrum of alternariol (AT) (1) in CD₃OD

Figure S5. ¹³C NMR Spectrum of alternariol (AT) (1) in CD₃OD

Figure S6. COSY Spectrum of alternariol (AT) (1) in CD₃OD

Figure S7. HSQC Spectrum of alternariol (AT) (1) in CD₃OD

Figure S8. HMBC Spectrum of alternariol (AT) (1) in CD₃OD

Figure S9. ¹H NMR spectrum of 5'-hydroxy-alternariol (HAT) (2) in DMSO-*d*₆

Figure S10. ¹³C NMR Spectrum of 5'-hydroxy-alternariol (HAT) (2) in DMSO-*d*₆

Figure S11. COSY Spectrum of 5'-hydroxy-alternariol (HAT) (2) in DMSO-*d*₆

Figure S12. HSQC Spectrum of 5'-hydroxy-alternariol (HAT) (2) in DMSO-*d*₆

Figure S13. HMBC Spectrum of 5'-hydroxy-alternariol (HAT) (2) in DMSO-*d*₆

Figure S14. ¹H NMR Spectrum of mycoepoxydiene (MED) (3) in DMSO-*d*₆

Figure S15. ¹³C NMR Spectrum of mycoepoxydiene (MED) (3) in DMSO-*d*₆

Figure S16. COSY Spectrum of mycoepoxydiene (MED) (3) in DMSO-*d*₆

Figure S17. HSQC Spectrum of mycoepoxydiene (MED) (3) in DMSO-*d*₆

Figure S18. HMBC Spectrum of mycoepoxydiene (MED) (3) in DMSO-*d*₆

Figure S19. Plots of root mean square deviation (RMSD) during 1 ns MD simulation of the complex with (a) hMAO-A and AT, and (b) hMAO-B and AT




Figure S1. Percentage purity of AT (1).




Figure S2. Percentage purity of HAT (2).




Figure S3. Percentage purity of MED (3).




Figure S4. ^1H NMR spectrum of Alternariol (AT) (**1**) in CD_3OD .




Figure S5. ^{13}C NMR spectrum of Alternariol (AT) (**1**) in CD_3OD .




Figure S6. COSY spectrum of Alternariol (AT) (**1**) in CD_3OD .




Figure S7. HSQC spectrum of Alternariol (AT) (**1**) in CD_3OD .




Figure S8. HMBC spectrum of Alternariol (AT) (**1**) in CD_3OD .




Figure S9. ^1H NMR Spectrum of 5'-hydroxy-alternariol (HAT) (**2**) in $\text{DMSO}-d_6$.




Figure S10. ^{13}C NMR Spectrum of 5'-hydroxy-alternariol (HAT) (2) in $\text{DMSO}-d_6$.




Figure S11. COSY Spectrum of 5'-hydroxy-alternariol (HAT) (2) in $\text{DMSO}-d_6$.




Figure S12. HSQC Spectrum of 5'-hydroxy-alternariol (HAT) (**2**) in $\text{DMSO}-d_6$.




Figure S13. HMBC Spectrum of 5'-hydroxy-alternariol (HAT) (**2**) in $\text{DMSO}-d_6$.




Figure S14. ¹H NMR spectrum of Mycoepoxydiene (MED) (**3**) in DMSO-*d*₆.




Figure S15. ¹³C NMR Spectrum of Mycoepoxydiene (MED) (**3**) in DMSO-*d*₆.




Figure S16. COSY Spectrum of Mycoepoxydiene (MED) (3) in $\text{DMSO}-d_6$.




Figure S17. HSQC Spectrum of Mycoepoxydiene (MED) (3) in $\text{DMSO}-d_6$.




Figure S18. HMBC Spectrum of Mycoepoxydiene (MED) (3) in $\text{DMSO}-d_6$.




Figure S19. Plots of root mean square deviation (RMSD) during 1 ns MD simulation of (a) hMAO-A and (b) hMAO-B complexes with AT.